Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study

Abstract Background The Canadian Bleeding Disorders Registry (CBDR) captures data from 24 hemophilia treatment centers and patients directly. Nonacog beta pegol (N9‐GP) was approved in Canada in 2018. Objectives To assess treatment outcomes following switching to N9‐GP in a real‐world setting. Metho...

Full description

Bibliographic Details
Main Authors: Davide Matino, Alfonso Iorio, Arun Keepanasseril, Federico Germini, Alexandre Caillaud, Manuel Carcao, Julia Hews‐Girard, Emma Iserman, Paula James, Adrienne Lee, Chai W. Phua, Haowei (Linda) Sun, Jerome Teitel, Man‐Chiu Poon
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
Canada
hemophilia B
N9‐GP
nonacog beta pegol
prophylaxis
real‐world
Online Access:https://doi.org/10.1002/rth2.12661

Internet

https://doi.org/10.1002/rth2.12661

Similar Items